Study identifier:NIS-OKR-CAS-2010/1
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Comparison of bone mineral loss in prostate cancer patients who is receiving GnRH agonist and -plus anti-androgen agent
GnRH agonist alone vs. GnRH agonist plus anti-androgen combination treated prostate cancer patients
-
No
-
Male
312
Observational
50 Years +
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Feb 2015 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
A Total of 250 prostate cancer patients receiving GnRH agonist | - |
B Total of 250 prostate cancer patients receiving GnRH agonist plus anti-androgen agent | - |